Vasomotor Symptoms clinical trials

Explore recruiting vasomotor symptoms clinical trials.

Recruiting vasomotor symptoms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Vasomotor Symptoms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women with Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Hungary, Denmark, Italy, Czechia, Germany, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks and optionally for additional up to 3.5 years in women with, or at high risk for developing hormone-receptor positive breast cancer

Hungary, Finland, Poland, France, Spain, Portugal +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality and mood in postmenopausal women.

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

(22424) Exploratory, randomized, non-blinded, crossover study to investigate the relative bioavailability of different elinzanetant soft gel capsules in healthy participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to learn how a high-fat meal affects the way elinzanetant is taken up by the body in healthy women

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

(22081) Open-label, fixed sequence crossover study to determine the effects of a single dose of elinzanetant (BAY 3427080) on the pharmacokinetics of dabigatran etexilate in healthy participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Vasomotor Symptoms trials by city

Vasomotor Symptoms in Toronto Vasomotor Symptoms in Vancouver Vasomotor Symptoms in Montreal Vasomotor Symptoms in Calgary Vasomotor Symptoms in Edmonton Vasomotor Symptoms in Ottawa Vasomotor Symptoms in Winnipeg Vasomotor Symptoms in Quebec City Vasomotor Symptoms in Hamilton Vasomotor Symptoms in Kitchener Vasomotor Symptoms in London Vasomotor Symptoms in Halifax Vasomotor Symptoms in New York Vasomotor Symptoms in Los Angeles Vasomotor Symptoms in Chicago Vasomotor Symptoms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease